Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indirubin-3'-oxime-O-acetic acid
- Development stage
- Preclinical
- Lead developer
- Perha Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Topical, Oral
01
Overview
Indirubin-3'-oxime-O-acetic acid (I3MO) is a synthetic, water-soluble derivative of the natural alkaloid indirubin. It is characterized by the presence of a carboxymethyl group on the oxime moiety at the 3' position, which significantly improves its pharmacological profile compared to the parent indirubin. The compound acts as a potent, ATP-competitive inhibitor of several protein kinases, with high affinity for **glycogen synthase kinase-3 beta (GSK-3β)** and **cyclin-dependent kinases (CDKs)**, including CDK1 and CDK5. By inhibiting GSK-3β, it stabilizes β-catenin and activates Wnt signaling, a pathway crucial for stem cell maintenance and neuroprotection. Its inhibition of CDKs induces cell cycle arrest and apoptosis, positioning the compound as a research candidate for various cancers, including chronic myeloid leukemia. Due to its solubility and potency, it is widely utilized as a biochemical probe in the study of kinase-mediated signaling and cell cycle regulation.
- Other names
- 2-({[(3E)-2'-oxo-1',2'-dihydro-3H-2,3'-biindol-3-ylidene]amino}oxy)acetic acid({[(3E)-2'-Oxo-2',7'-dihydro-2,3'-biindol-3(7H)-ylidene]amino}oxy)acetic acid
02
Targets
CDK2 (Cyclin-dependent kinase 2)CDK9 (Cyclin-dependent kinase 9)GSK3 (Glycogen synthase kinase 3 beta)JNK (Mitogen-activated protein kinase kinase kinase family)CDK1 (Cyclin-dependent kinase 1)CDK5 (Cyclin-dependent kinase 5)
Beyond the preview
Go deeper on indirubin-3'-oxime-O-acetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indirubin-3'-oxime-O-acetic acid.